文献速递胸部肿瘤

Asandeutertinib 在晚期 EGFR 突变 NSCLC 中的安全性、药代动力学与疗效:一项 1 期剂量递增与剂量扩展研究

Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study.
PubMed 文献 · J Thorac Oncol · 2025-02-08

这项 1 期研究评估了氘代奥希替尼衍生物 TY-9591(asandeutertinib)在晚期 EGFR 突变 NSCLC 患者中的安全性、药代动力学和初步疗效。剂量递增阶段(n=19)未观察到剂量限制性毒性,未达到最大耐受剂量;剂量扩展阶段(n=79)一线治疗的中位无进展生存期为 21.5 个月(95%CI:17.3-27.3),确认客观缓解率为 85.9%(95%CI:76.2-92.7)。

要点

  • 剂量递增 20-200 mg 每日一次未观察到剂量限制性毒性,未达到最大耐受剂量。
  • 105 例患者中治疗相关不良事件发生率为 95.2%,≥3 级治疗相关不良事件占 30.5%。
  • 剂量扩展阶段一线治疗确认客观缓解率 85.9%,中位无进展生存期 21.5 个月。

核心结论

  • TY-9591 在 EGFR 突变 NSCLC 中报告了良好的安全性特征和可观的疗效,尤其在 L858R 突变患者中。

研究设计与样本

  • 这项 1 期研究纳入晚期 EGFR 突变(最常见为外显子 19 缺失或 L858R)NSCLC 患者,共 105 例(剂量递增 n=19;剂量扩展 n=86)。
  • 剂量递增阶段 TY-9591 从 20 至 200 mg 每日一次给药,评估剂量限制性毒性和最大耐受剂量。
  • 剂量扩展阶段患者接受 80、120 或 160 mg 剂量治疗,进一步评估安全性、药代动力学和初步疗效。

主要发现

  • 剂量递增阶段未观察到剂量限制性毒性,未达到最大耐受剂量。
  • 治疗相关不良事件见于 100 例患者(95.2%),最常见为白细胞计数降低(54.3%)、中性粒细胞计数降低(46.7%)、血肌酸磷酸激酶升高(39.0%)和贫血(39.0%)。
  • 32 例患者(30.5%)发生 3 级或以上治疗相关不良事件。
  • 药代动力学分析发现 TY-9591 具有良好的特征,活性代谢产物水平降低。
  • 剂量扩展阶段(n=79)一线 EGFR 突变(外显子 19 缺失或 L858R)NSCLC 的中位无进展生存期为 21.5 个月(95%CI:17.3-27.3),确认客观缓解率为 85.9%(95%CI:76.2-92.7)。

关键数值与推荐

  • 剂量递增阶段 TY-9591 给药剂量范围为 20 至 200 mg 每日一次。
  • 剂量扩展阶段 TY-9591 给药剂量为 80、120 或 160 mg。
  • 剂量扩展阶段(n=79)一线治疗确认客观缓解率为 85.9%(95%CI:76.2-92.7),中位无进展生存期为 21.5 个月(95%CI:17.3-27.3)。
  • L858R 突变患者(n=36)确认客观缓解率为 86.1%(95%CI:70.5-95.3),中位无进展生存期为 19.3 个月(95%CI:13.1-23.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This phase 1 study evaluated the safety, pharmacokinetics, and preliminary efficacy of TY-9591 (asandeutertinib), a deuterated osimertinib derivative. METHODS: Patients with advanced EGFR-mutated (most commonly exon 19 deletions or L858R) NSCLC were enrolled. In the dose-escalation phase, TY-9591 was administered from 20 to 200 mg once daily to assess dose-limiting toxicities and the maximum tolerated dose. In the dose-expansion phase, patients were treated with 80, 120, or 160 mg doses to further evaluate safety, pharmacokinetics, and preliminary efficacy. RESULTS: A total of 105 patients were enrolled (dose-escalation: n = 19; dose-expansion: n = 86). During the dose escalation phase, no dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) were reported in 100 patients (95.2%). The most common TRAEs were decreased white blood cell count (54.3%), decreased neutrophil count (46.7%), increased blood creatine phosphokinase (39.0%), and anemia (39.0%). Of these patients, 32 (30.5%) experienced grade 3 or higher TRAEs. Pharmacokinetic analysis found that TY-9591 had a favorable profile with reduced levels of active metabolites. During the dose-expansion phase (n = 79), the median progression-free survival for first-line EGFR-mutated (exon 19 deletions or L858R) NSCLC was 21.5 months (95% confidence interval [CI]: 17.3-27.3), whereas the confirmed objective response rate was 85.9% (95% CI: 76.2-92.7). In patients with L858R mutations (n = 36), the median progression-free survival was 19.3 months (95% CI: 13.1-23.5), and the confirmed objective response rate was 86.1% (95% CI: 70.5-95.3). CONCLUSION: TY-9591 reported a favorable safety profile and substantial efficacy in treating EGFR-mutated NSCLC, particularly in patients with L858R mutations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Han B, Liu J, Wu L, et al. Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study. J Thorac Oncol. 2025. PMID: 39929334. doi:10.1016/j.jtho.2025.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。